Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI-UnitedHealth Global Health Centers of Excellence Program.
Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI-UnitedHealth Global Health Centers of Excellence Program.
复制标题
DOI:
10.1016/j.gheart.2015.12.016
复制
发表时间:
2016-03
期刊:
影响因子:
3.7
通讯作者:
National Health, Lung, and Blood Institute–UnitedHealth Global Health Centers of Excellence Collaborators
中科院分区:
文献类型:
--
作者:
Engelgau MM;Sampson UK;Rabadan-Diehl C;Smith R;Miranda J;Bloomfield GS;Belis D;Narayan KM;National Health, Lung, and Blood Institute–UnitedHealth Global Health Centers of Excellence Collaborators
Between 1990 and 2010 the global non-communicable diseases (NCDs) burden increased from 43% to 54% of the total disease burden. 1 In 2012, globally, almost three quarters (74%) of all the NCD burden occurred in low-and middle-income countries. 2 Population growth and population aging have contributed substantially to the expanding NCD burden trends–both of which are rapidly occurring within low and middle income country populations. 3, 4 Effectively tackling this growing NCD burden in low-and middle-income country settings presents a major challenge, yet, is an achievable task. 2, 3, 5Today, many effective NCD interventions are available. The World Economic Forum and World Health Organization (WHO) recently developed a report targeted at decision makers, civil society, and the private sector, that provides assessments of the economic impact of noncommunicable diseases and costs of scaling up a core of proven-effective interventions within low-and middle income counties. 6 However, responding to these challenges in lowand middle-income countries will need local research capacity building, 7 so that interventions are driven by in-country knowledge-bases provided through research performed in low-and middle-income countries. Yet, research infrastructure and outputs in low and middle income countries are woefully inadequate, and the data from these settings are scarce. 3, 8 This situation poses problems both for implementation of known interventions and also for tackling low-and middle-income country disease patterns, phenotypes that might differ from high-income countries.